Three Meds for Diabetic Macular Edema Compared

This article originally appeared here.
Share this content:
Three Meds for Diabetic Macular Edema Compared
Three Meds for Diabetic Macular Edema Compared

THURSDAY, Feb. 19, 2015 (HealthDay News) -- New research compared three leading drugs for diabetic macular edema -- bevacizumab (Avastin), aflibercept (Eylea), and ranibizumab (Lucentis) -- and although aflibercept came out on top, all were effective options. The study was published online Feb. 18 in the New England Journal of Medicine.

The new study included 660 people, averaging 61 years of age, with diabetic macular edema. All of the patients had been diagnosed with either type 1 or type 2 diabetes for an average of 17 years. Patients were randomly assigned to take one of the three drugs and had their vision assessed a year later.

Among patients whose vision was 20/50 or worse at the start of the trial, those who took aflibercept had greater vision improvement than those who took bevacizumab or ranibizumab. However, the researchers stressed that all three drugs offered similar vision improvement in patients whose vision at the start of the study was rated as anywhere from 20/40 to 20/32. The three drugs were also similar in terms of safety.

Ronald Gentile, M.D., is a professor of ophthalmology at the New York Ear and Eye Infirmary of Mount Sinai in New York City, and was an investigator on the trial. He told HealthDay that "the importance of this study can't be overstated. These one-year results highlight the fact that all the drugs studied -- Eylea, Avastin, and Lucentis -- are potentially effective [treatment] options." Another expert, not involved in the research, noted cost: "Eylea costs about $1,900 per injection, Lucentis about $1,200, and Avastin costs about $70 for each monthly treatment for diabetic macular edema," Mark Fromer, M.D., an ophthalmologist at Lenox Hill Hospital in New York City, told HealthDay. Currently, "Avastin is used worldwide much more readily than the other drugs because of cost, and in most cases Avastin will accomplish the same goal."

The study was funded by the U.S. National Eye Institute.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

California Lawsuit Claims AbbVie Paid Doctors to Prescribe Humira

California Lawsuit Claims AbbVie Paid Doctors to Prescribe ...

Claims physicians prescribed Humira because of financial kickbacks, not as best drug for patient

Patient-Directed IV Remifentanil Cuts Epidural Conversions

Patient-Directed IV Remifentanil Cuts Epidural Conversions

Patient-controlled remifentanil reduces proportion of conversions versus intramuscular pethidine

Pediatricians Have Role in Supporting Transgender Youth

Pediatricians Have Role in Supporting Transgender Youth

Recommendations developed for comprehensive care for youth identifying as transgender, gender diverse

is free, fast, and customized just for you!




Already a member?

Sign In Now »